Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial

LESSONS LEARNED. Adjuvant treatment with zoledronic acid did not decrease the recurrence rate of giant cell tumor of bone (GCTB) in this study. The efficacy could not be determined because of the small sample size. GCTB recurrences, even in the denosumab era, are still an issue; therefore, a randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipplaa, Astrid, Kroep, Judith R., van der Heijden, Lizz, Jutte, Paul C., Hogendoorn, Pancras C.W., Dijkstra, Sander, Gelderblom, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656477/
https://www.ncbi.nlm.nih.gov/pubmed/31040253
http://dx.doi.org/10.1634/theoncologist.2019-0280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656477/
https://www.ncbi.nlm.nih.gov/pubmed/31040253
http://dx.doi.org/10.1634/theoncologist.2019-0280

Ejemplares similares